Variant IgG3 Rituxan and therapeutic use thereof
    1.
    发明申请
    Variant IgG3 Rituxan and therapeutic use thereof 审中-公开
    变体IgG3赖曲康及其治疗用途

    公开(公告)号:US20020128448A1

    公开(公告)日:2002-09-12

    申请号:US09982849

    申请日:2001-10-22

    发明人: Mitchell E. Reff

    IPC分类号: C07K014/46 A61K039/395

    摘要: Monoclonal anti-human CD20 antigen binding antibodies containing human IgG3 constant domains are provided. These antibodies possess effector functions that render them well suited for use in therapeutic methods, especially treatments wherein inhibition of B cell function or B cell number is therapeutically desirable.

    摘要翻译: 提供含有人IgG3恒定结构域的单克隆抗人CD20抗原结合抗体。 这些抗体具有使其非常适合用于治疗方法的效应子功能,特别是其中B细胞功能或B细胞数目的抑制在治疗上是理想的治疗。

    Polycistronic expression of antibodies
    5.
    发明申请
    Polycistronic expression of antibodies 审中-公开
    抗体的多顺反子表达

    公开(公告)号:US20030157641A1

    公开(公告)日:2003-08-21

    申请号:US10295823

    申请日:2002-11-18

    摘要: Described herein is a novel expression system for producing multiple gene products of interest from a single polycistronic construct. In particular, the expression system contains a polycistronic vector capable of expressing functional antibodies in eukaryotic host cells, which vector contains at least the following elements operably linked in the 5null to 3null orientation: a promoter operable in a eukaryotic cell; a DNA sequence encoding at least the variable region of an antibody light chain; an internal ribosome entry site (IRES); and at least one DNA sequence encoding an antibody heavy chain. Also disclosed are mammalian cells containing the polycistronic expression vector, and a method of producing functional antibodies in mammalian cells transfected with the polycistronic expression vector.

    摘要翻译: 本文描述的是用于从单一多顺反子构建体产生感兴趣的多个基因产物的新型表达系统。 特别地,表达系统包含能够在真核宿主细胞中表达功能性抗体的多顺反子载体,该载体至少包含以5'至3'取向可操作地连接的以下元件:可在真核细胞中可操作的启动子; 编码抗体轻链的至少可变区的DNA序列; 内部核糖体进入位点(IRES); 和编码抗体重链的至少一个DNA序列。 还公开了含有多顺反子表达载体的哺乳动物细胞,以及在用多顺反子表达载体转染的哺乳动物细胞中产生功能性抗体的方法。